M
Michael A. Matthay
Researcher at University of California, San Francisco
Publications - 1063
Citations - 110857
Michael A. Matthay is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Lung injury & Lung. The author has an hindex of 151, co-authored 998 publications receiving 98687 citations. Previous affiliations of Michael A. Matthay include University of California & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL‐37
Anna Krasnodembskaya,Yuanlin Song,Xiaohui Fang,Naveen Gupta,Vladimir B. Serikov,Jae-Woo Lee,Michael A. Matthay +6 more
TL;DR: Human bone marrow‐derived MSCs possess direct antimicrobial activity, which is mediated in part by the secretion of human cathelicidin hCAP‐18/ LL‐37, analysis of expression of major antimicrobial peptides indicated.
Journal ArticleDOI
Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury.
Polly E. Parsons,Mark D. Eisner,B. Taylor Thompson,Michael A. Matthay,Marek Ancukiewicz,Gordon R. Bernard,Arthur P. Wheeler +6 more
TL;DR: In patients with acute lung injury, plasma interleukin-6 and interleucin-8 levels are associated with morbidity and mortality, suggesting that clinical risk factor should be considered when both developing and testing therapeutic interventions.
Journal ArticleDOI
Sepsis: pathophysiology and clinical management
TL;DR: Outcomes in sepsis have greatly improved overall, probably because of an enhanced focus on early diagnosis and fluid resuscitation, the rapid delivery of effective antibiotics, and other improvements in supportive care for critically ill patients.
Journal ArticleDOI
Lung epithelial fluid transport and the resolution of pulmonary edema.
TL;DR: There is convincing evidence that active sodium and chloride transporters are expressed in the distal lung epithelium and are responsible for the ability of the lung to remove alveolar fluid at the time of birth as well as in the mature lung when pathological conditions lead to the development of pulmonary edema.
Journal ArticleDOI
Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung.
TL;DR: Treatment with allogeneic human MSCs or the conditioned medium restores normal fluid balance in an ex vivo perfused human lung injured by E. coli endotoxin.